Image Credit: Health and me
There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.
The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.
While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.
Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.
While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.
Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.
Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.
RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.
Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.
The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.
Also Read: Is US Preparing For A Quad- demic 2025?
The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:
While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.
If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.
As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.
Credit: AI
The FSSAI recently issued notices to three food business operators over what it described as misleading claims and labelling violations. The companies that have received notices are Heritage Foods Ltd for its paneer, Dia Foods for La Casa Vegan Hazelnut Chocolate Spread, and Cipzer Nutraceuticals for its juice capsules.
The food regulatory body directed the companies to provide explanations within seven days why action should not be initiated under the Food Safety and Standards Act, 2006.
The move is part of the regulator's broader ongoing crackdown on deceptive food packaging and marketing claims aimed at protecting consumers.
Also read: FSSAI Targets 6 Energy Drink Brands; Experts Link Them to Obesity, Liver Problems
FSSAI issued a notice to Heritage Foods, objecting to the use of the term “Fresh Paneer” on the packaging. It stated that the claim term does not meet the conditions laid down under Schedule V governing the use of the word “fresh”.
According to the regulator, the label “Fresh Paneer” is liable to mislead consumers because it does not satisfy the prescribed criteria for using the term.
FSSAI also issued a notice to Dia Foods over its La Casa Vegan Hazelnut Chocolate Spread, alleging that several claims displayed on the packaging could mislead consumers. Among the claims questioned are:
The regulator further pointed out that the product uses the phrase "100% Organic & Vegan”, which could be misleading as it has not obtained approvals like organic and vegan food.
Further, according to FSSAI, the packaging does not display the mandatory organic certification marks, including the Jaivik Bharat logo required under Indian regulations.
It also objected to its use of “100%” as the food regulatory body has stated that it cannot be defined under FSS Act, 2006.
Also read: Popular Biscuit Brand Under FSSAI Scrutiny For Misleading ‘100% Atta’ & ‘No Added Sugar’ Claims
A third notice was issued to Cipzer Nutraceuticals over its juice capsules. FSSAI said the product carries claims that violate food labelling and advertising regulations.
In its notice, it said that the product carried the claim “FSSAI-approved” which could imply that FSSAI specifically endorsed it.
Other reasons listed in the complaint stated that the product boasted of claims like “Boost your immune system” and “remove toxins from your body”, which had no scientific backing. It also said the product’s packaging depicted pictures of various vegetables that were listed in the ingredient list.
The regulatory body added that the product also claimed the presence of Vitamin C and Vitamin E but failed to substantiate it scientifically.
The makers also claimed that the capsules are “made from organic vegetables”. FSSAI said that it could mislead the consumers as it does not carry the prescribed organic certification, including Jaivik Bharat Logo.
The latest notices are part of FSSAI's ongoing crackdowns against misleading food claims. In recent weeks, the regulator has issued notices to several food companies over the use of terms like “100%,” “healthy,” “organic,” “natural,” and “fresh” as they do not comply with food labelling and advertising regulations.
The regulator has maintained that such claims can influence consumer purchasing decisions and must be scientifically substantiated and legally compliant.
Prominent brands that faced FSSAI scrutiny includes Red Bull Energy Drink, PepsiCo – Adrenaline Rush Energy Drink, Reliance Consumer Products – Campa Energy Gold Boost, Sting Energy Drink, Hell Energy, Coca-Cola-backed Monster, Eat Fit Digestive Biscuits, Emami (Healthy & Tasty), Health Aid, Troovy, The Healthy Factory, Healthy Master, Healthy Choice, Plan B Foods, and Neuherbs.
Also read: FSSAI Tightens Food Safety Norms, Mandates Food-Grade Knives, Cutting Tools
HealthandMe had reported food contamination from Indore's Bhagirathpura, the same place that was the epicenter of water contamination that claimed many lives. HealthandMe also reported the news of Horlicks adulteration in Odisha.
In another news, bacteria were found in Amul milk packages, along with Mother Dairy and Country Delight. Eggoz, too, landed in a controversy, when a YouTube video went viral claiming that the sample tested positive for Nitrofuran.
MicrobioTx, a Bengaluru-based gut health startup, tested samples from urban populations across 9 Indian states and 14 cities and found that people are significantly exposed to pesticides, insecticides, antibiotics, steroidal growth regulators, and forever chemicals.
The independent study reported the following findings:
Credit: US CDC
The cyclospora parasite outbreak in the US is continuing to grow, with cases nearing 900, according to local health officials.
While infections have been reported in about 18 states, Michigan and Ohio continue to see the highest number of cases of the intestinal infection.
As of July 6, 678 cases of cyclosporiasis had been confirmed, an official from the Michigan Department of Health and Human Services (MDHHS) told ABC News. This is an increase from roughly 300 cases reported last week. The state annually records up to 50 cases, but the current outbreak is about 13.5 times higher than average.
According to Dr. Natasha Bagdasarian, an infectious disease physician, epidemiologist, and the chief medical executive for the state of Michigan, the figure is a "moving target," meaning cases are likely to continue rising.
"There is a significant lag time between exposure to contaminated produce or contaminated materials and development of symptoms," she told ABC News. "So it can take a week, sometimes even two weeks between exposure and development of symptoms."
In Ohio, there were 177 cases of cyclosporiasis as of July 2, Ken Gordon, press secretary for the Ohio Department of Health's communications office, was quoted as saying.
Cases have been confirmed across 43 counties in Ohio so far this year, according to Gordon. Nearly 171 cases have been reported since June 20.
Meanwhile, the Centers for Disease Control and Prevention (CDC) reported that 145 cases had been detected in 17 states since May 1, excluding Michigan, as of June 16, with at least 20 people hospitalized. No deaths have been reported.
The CDC said cases ranged in age from 5 to 86 years, with a median age of 42. About 61 per cent of patients were female.
So far, no cases have been linked between states, and health officials are still investigating whether there is a common source of the outbreak in Michigan.
Also read: Cyclospora Parasite Spreads to More US States: Foods to Avoid Right Now
The CDC recommends following safe food handling practices to reduce the risk of infection:
The parasite spreads through food or water contaminated with human feces and is not spread directly from person to person.
According to Dr. Darien Sutton, an emergency medicine physician, proper handwashing is very important.
"This type of parasite doesn't easily go away with alcohol-based hand sanitizer. So, good old handwashing is really key here," said the ABC News medical correspondent.
Cyclospora cayetanensis is a parasite that causes cyclosporiasis, a form of food poisoning.
People can become infected through contaminated food or water. The infection causes watery diarrhea and other intestinal symptoms.
A Cyclospora infection can be mild or severe and may last for weeks or even months. It is typically treated with antibiotics.
People with weakened immune systems, such as those with HIV/AIDS or cancer, are at greater risk of severe disease.
Symptoms of cyclosporiasis usually begin within a week of exposure to contaminated food or water and include:
Credit: AI
The launch of the weight-loss drug Wegovy has sparked fresh concerns among pharmacists in the UK, who warn that the new tablet format could make it easier for manufacturers to produce and sell counterfeit medicines.
The once-daily semaglutide pill, developed by Novo Nordisk, recently became available through private high street and online pharmacies after receiving approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).
While the pill is expected to help patients who are reluctant to use injections, experts fear it may also increase the risk of a growing black market for fake weight-loss drugs.
According to a survey conducted by the National Pharmacy Association (NPA) with 310 pharmacies, 97% believe that the weight loss tablet could lead to an increase in counterfeit products being sold unlawfully.
Olivier Picard, chairman of the National Pharmacy Association said, “As this survey shows, pharmacies are concerned about a dangerous and growing black market for weight loss medicines, with tablet form of medication likely to be easier for criminals to counterfeit.”
He said that all patients must visit an authorised pharmacy for Wegovy pills.
He added: “Patients should only ever obtain weight loss medication from a regulated pharmacy after an appropriate consultation with a healthcare professional. Fake medicines pose a serious risk to health because they may contain harmful ingredients or incorrect doses.”
Also read: Wegovy Weight Loss Pill Available in UK Pharmacies From Today: All You Should Know
Unlike injectable medications of GLP-1, tablets often require less sophisticated manufacturing equipment, which makes it easier to make counterfeits.
As the medicated weight loss market is rising after the popularity of GLP-1 medications increased, criminals can produce fake pills on a large scale, using simple equipment.
Counterfeit GLP-1 medicines have already become a growing global concern. In September 2025, the European Medicines Agency (EMA) said that there had been a sharp rise in illegal forms of semaglutide and other GLP-1 medicines online.
The agency also warned that these fake medicines may contain no active ingredient, improper doses, or harmful substances that can lead to failure of treatment or serious health complications.
Demand for GLP-1 medicines such as Wegovy and Mounjaro has soared worldwide as studies continue to demonstrate significant weight loss benefits.
Also read: Can Ozempic-Like GLP-1 Drugs Slow Aging, Boost Longevity?
Clinical trials of the oral Wegovy tablet have shown participants taking the highest dose lost approximately 14% to 17% of their body weight over 64 weeks when combined with diet and exercise. However, pharmacists say the popularity of these treatments has also created opportunities for fraudsters.
Experts urge consumers to avoid purchasing weight-loss medicines from unofficial online sellers or social media advertisements, regardless of how attractive the prices appear.
Genuine GLP-1 medicines require a medical consultation and prescription, and authorised pharmacies carry out necessary clinical checks before selling them.
The semaglutide (Wegovy) tablet is the first oral glucagon-like peptide-1 (GLP-1) medicine approved in the UK for weight loss.
It can be prescribed alongside a reduced-calorie diet and increased physical activity for adults who have obesity (BMI of 30 or above), or are overweight (BMI between 27 and 30), and have at least one weight-related comorbidity
© 2024 Bennett, Coleman & Company Limited